| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$289 |
Update - Notification of buy-back - AMH
|
29 Apr 2026 8:54AM |
$0.915 |
$0.920 |
risen by
0.55%
|
|
| Dexus Industria REIT (DXI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$756 |
Update - Notification of buy-back - DXI
|
29 Apr 2026 8:54AM |
$2.450 |
$2.420 |
fallen by
1.22%
|
|
| Australian Gold and Copper Ltd (AGC) ORDINARY FULLY PAID |
Materials |
$36 |
Step Out Drilling Underway at Achilles
|
29 Apr 2026 8:54AM |
$0.165 |
$0.125 |
fallen by
24.24%
|
|
AGC - Price-sensitive ASX Announcement
Full Release
Key Points
- Step out drilling underway at Achilles with potential to double the depth of known mineralisation.
- First hole targets resource growth to over 550 metres down dip and 200 metres below the deepest hole for existing MRE.
- Notable drill results include 20.8m at 99g/t AgEq from 209m in hole A3RCD093 and a new zone discovery in A3RCD093.
- AGC aims to significantly increase contained ounces and leverage their value.
- The Achilles discovery hosts an initial 38.5Moz AgEq Resource, 58% indicated.
- Current drilling aims to extend the depth of mineralisation to 500m.
- AGC is focusing on two growth pathways: expanding the initial resource and fast-tracking mining potential.
- Drilling at Achilles is part of a dual track resource growth strategy with work also at Browns–Evergreen.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$66 |
Botanix Q3 FY26 Investor Update Webinar Presentation
|
29 Apr 2026 8:53AM |
$0.030 |
$0.024 |
fallen by
20%
|
|
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$766 |
Update - Notification of buy-back - DJW
|
29 Apr 2026 8:53AM |
$2.910 |
$2.920 |
risen by
0.34%
|
|
| Rokeby Resources Limited (RKB) ORDINARY FULLY PAID |
Materials |
$12 |
March Quarterly Activities and Cash Flow Reports
|
29 Apr 2026 8:52AM |
$0.005 |
$0.004 |
fallen by
11.11%
|
|
RKB - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash used in operating activities: $250,000 for the quarter, $976,000 year-to-date.
- Net cash used in investing activities for exploration: $164,000 for the quarter, $1,184,000 year-to-date.
- Net cash from financing activities: $1,992,000.
- Significant focus on exploration and evaluation.
- Details on various exploration projects and tenement status included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$31 |
Emyria Extends National Expansion into New South Wales
|
29 Apr 2026 8:52AM |
$0.050 |
$0.038 |
fallen by
24%
|
|
EMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Emyria expands into New South Wales with a new clinic at Matilda Nepean Private Hospital.
- The expansion provides Emyria a presence in every major state in Australia.
- The new clinic will commence operations around Q3 CY2026.
- Four new treatment beds will be added, increasing the total capacity.
- The expansion supports the Empax Global Partnership Program.
- Recruitment for the New South Wales clinical workforce is underway.
- Six new Authorised Prescriber approvals have been received.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cosmos Exploration Limited (C1X) ORDINARY FULLY PAID |
Materials |
$27 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Apr 2026 8:52AM |
$0.240 |
$0.110 |
fallen by
54.17%
|
|
C1X - Price-sensitive ASX Announcement
Full Release
Key Points
- Completed an A$5.0 million placement of shares.
- Raised funds to support exploration programs and EAU Lithium acquisition.
- Reported a net cash inflow from financing activities of A$4.185 million.
- Cash balance at quarter-end was A$3.792 million.
- Field-based exploration was not conducted due to seasonal constraints.
- Technical evaluations continued across projects.
- Acquisition and exploration plans awaiting shareholder approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fulcrum Lithium Ltd (FUL) ORDINARY FULLY PAID |
Materials |
$5 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Apr 2026 8:52AM |
$0.115 |
$0.065 |
fallen by
43.48%
|
|
FUL - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of Alkali Flats Phase 3 drilling with thick lithium mineralization confirmed.
- CSAMT survey utilized for exploration at Dry Canyon.
- Net cash used in operating activities was $1,528,000 for the quarter.
- Promising outlook for lithium pricing.
- Strategic advances in exploration positioning Fulcrum for resource estimation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resonance Health Limited (RHT) ORDINARY FULLY PAID |
Health Care |
$21 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Apr 2026 8:51AM |
$0.043 |
$0.045 |
risen by
4.65%
|
|
RHT - Price-sensitive ASX Announcement
Full Release
Key Points
- Cash receipts of $4.4M with net operating cash inflow of $2.0M.
- The Group received a net R&D claim refund of $0.7M.
- Cash at bank of $4.4M at quarter-end with a net cash position of $1.8M after accounting for $2.6M in bank debt.
- Major pharma $13.8M clinical trial recruitment target expected to complete in April 2026.
- Continued strong Software-as-a-Medical-Device (SaMD) bid activity with forward orders and pipeline exceeding $10M.
- TrialsWest Osborne Park clinic exceeding expectations, with the Mandurah clinic also performing well.
- Completion of patient enrolment in the Non-Invasive MRI Liver Fibrosis proof-of-concept trial.
- Appointment of two Non-Executive Directors to strengthen Board capability.
- Focus on growth in three core business areas: Clinical Trial Management, SaMD, and Clinical Trial Site Services.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dexus Convenience Retail REIT (DXC) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$360 |
Update - Notification of buy-back - DXC
|
29 Apr 2026 8:51AM |
$2.730 |
$2.650 |
fallen by
2.93%
|
|
| Axel REE Limited (AXL) ORDINARY FULLY PAID |
Materials |
$8 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Apr 2026 8:51AM |
$0.071 |
$0.084 |
risen by
18.31%
|
|
AXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Advancements in Caladão REE-Gallium and Caldas REE Projects.
- Development of low-cost, modular ISR method for REE.
- Significant MREO and gallium recovery confirmed.
- De-risking ISR development at the Woolrich deposit.
- Cash and cash equivalents decreased to A$6,553,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Liontown Limited (LTR) ORDINARY FULLY PAID |
Materials |
$4,737 |
Early works and procurement underway for KV expansion
|
29 Apr 2026 8:51AM |
$2.370 |
$1.490 |
fallen by
37.13%
|
|
LTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Early works and procurement initiated for Kathleen Valley expansion
- Final Investment Decision expected end of Q1 FY2027
- Initial step in refreshing the 2021 expansion case
- Procurement includes a 5.5MW ball mill for increased capacity
- FY2026 early works expenditure anticipated at A$15-18 million
- A$12 million committed for ball mill over next 12 months
- Expansion expected to mitigate schedule and pricing risks
- Strengthened position in the lithium market
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hyterra Ltd (HYT) ORDINARY FULLY PAID |
Energy |
$28 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Apr 2026 8:51AM |
$0.015 |
$0.014 |
fallen by
10%
|
|
HYT - Price-sensitive ASX Announcement
Full Release
Key Points
- HyTerra focuses on geologic hydrogen and helium exploration.
- Advanced Nemaha Project in Kansas with upcoming production test.
- Collaborated with Prometheus Hydrogen for US demonstration.
- Entered MoU with ARA Natural Resources to explore in Oman.
- Reported $1.27 million cash at the end of the quarter.
- Launched an entitlement offer to raise $7 million.
- Strategic global engagements to expand hydrogen initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$66 |
Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
|
29 Apr 2026 8:50AM |
$0.030 |
$0.024 |
fallen by
20%
|
|
BOT - Price-sensitive ASX Announcement
Full Release
Key Points
- Total prescriptions shipped grew by 5% in Q3 FY26.
- Net revenue decreased to $6.9 million due to deductible reset.
- Botanix raised ~$45 million from capital raising efforts.
- API supply agreement renegotiated to defer payments.
- Manufacturing costs increased due to API purchase.
- Botanix confident in Sofdra sales momentum entering U.S. summer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kincora Copper Limited (KCC) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$18 |
Kincora Investor Presentation
|
29 Apr 2026 8:50AM |
$0.835 |
$0.850 |
risen by
1.80%
|
|
| G8 Education Limited (GEM) ORDINARY FULLY PAID |
Consumer Discretionary |
$116 |
Chair and CEO and MD Address to Shareholders
|
29 Apr 2026 8:49AM |
$0.240 |
$0.150 |
fallen by
37.50%
|
|
| Patrys Limited (PAB) ORDINARY FULLY PAID |
Health Care |
$27 |
Cleansing Notice
|
29 Apr 2026 8:48AM |
$0.030 |
$0.040 |
risen by
33.33%
|
|
| Cochlear Limited (COH) ORDINARY FULLY PAID |
Health Care |
$7,954 |
Application for quotation of securities - COH
|
29 Apr 2026 8:48AM |
$93.000 |
$121.620 |
risen by
30.77%
|
|
| Jindalee Lithium Limited (JLL) ORDINARY FULLY PAID |
Materials |
$44 |
Exploration Plan of Operations Update
|
29 Apr 2026 8:47AM |
$0.605 |
$0.350 |
fallen by
42.15%
|
|
| Omega Oil & Gas Limited (OMA) ORDINARY FULLY PAID |
Energy |
$362 |
Quarterly Activities Report and Appendix 5B
|
29 Apr 2026 8:46AM |
$0.990 |
$0.670 |
fallen by
32.32%
|
|
OMA - Price-sensitive ASX Announcement
Full Release
Key Points
- Omega Oil & Gas Limited (ASX: OMA) released its Quarterly Activities Report for the period ending 31 March 2026.
- Omega has secured $60 million in new equity to strengthen its balance sheet and fully fund its upgraded drilling program.
- The company plans to drill four vertical wells and one or two horizontal wells in the Taroom Trough, Queensland.
- Omega's strategy involves accelerating the appraisal of its acreage to demonstrate repeatable, commercial flow results.
- A significant focus is on the Canyon Project and ATP 2081 JV, where Omega holds a 45% interest.
- The company ended the quarter with a cash balance of $50 million, an increase from $43.4 million at the end of 2025.
- Omega is leveraging government support for the development of the Taroom Trough to streamline approvals and infrastructure development.
- The company is also focused on de-risking the Permian play and identifying 'sweet spots' for production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Adheris Health Limited (AHE) ORDINARY FULLY PAID |
Health Care |
$11 |
Q3 FY26 Results Presentation
|
29 Apr 2026 8:45AM |
$0.019 |
$0.017 |
fallen by
10.53%
|
|
AHE - Price-sensitive ASX Announcement
Full Release
Key Points
- Q3 FY26 revenue was $5.4 million, a decrease from Q3 FY25.
- Focus on expanding pharmacy network with digital connectivity.
- 13.5 million new digitally eligible patients added in Q3 FY26.
- Initiatives to diversify revenue towards non-vaccine and higher-margin solutions.
- Digital innovation strategy includes AI and enhanced patient experiences.
- Cost optimization strategies to reduce annual staff costs to $14.5 million.
- Targeting cashflow neutrality by Q4 FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,094 |
Update - Notification of buy-back - NEU
|
29 Apr 2026 8:45AM |
$11.930 |
$16.520 |
risen by
38.47%
|
|
| Nido Education Limited (NDO) ORDINARY FULLY PAID |
Consumer Discretionary |
$87 |
Postponement of Annual General Meeting
|
29 Apr 2026 8:45AM |
$0.375 |
$0.385 |
risen by
2.67%
|
|
| Doctor Care Anywhere Group PLC (DOC) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$45 |
Results of Meeting
|
29 Apr 2026 8:45AM |
$0.135 |
$0.123 |
fallen by
9.26%
|
|
Call 1300 880 160
Start a chat
Schedule a call
